Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.

ABSTRACT:

Importance

There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate.

Objective

To determine whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild AD.

Design, setting, and participants

Participants were recruited into a double-blind randomized clinical trial from May 23, 2014, to April 14, 2016, with 24 months of treatment and follow-up. This multicenter study in England and Scotland involved 32 National Health Service memory clinics within secondary specialist services for people with dementia. From 88

SUBMITTER: Howard R 

PROVIDER: S-EPMC6865324 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature